Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS) today and set a price target of $27. The company’s shares closed yesterday at $12.26.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 8.4% and a 42.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Xeris Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $27.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.98 and a one-year low of $6.85. Currently, Xeris Pharmaceuticals Inc has an average volume of 199.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
